CORESTEM Inc (166480) - Net Assets
Based on the latest financial reports, CORESTEM Inc (166480) has net assets worth ₩40.62 Billion KRW (≈ $27.53 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩113.27 Billion ≈ $76.76 Million USD) and total liabilities (₩72.65 Billion ≈ $49.24 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CORESTEM Inc (166480) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩40.62 Billion |
| % of Total Assets | 35.86% |
| Annual Growth Rate | 9.86% |
| 5-Year Change | 17.7% |
| 10-Year Change | -22.91% |
| Growth Volatility | 84.4 |
CORESTEM Inc - Net Assets Trend (2014–2024)
This chart illustrates how CORESTEM Inc's net assets have evolved over time, based on quarterly financial data. Also explore CORESTEM Inc total assets for the complete picture of this company's asset base.
Annual Net Assets for CORESTEM Inc (2014–2024)
The table below shows the annual net assets of CORESTEM Inc from 2014 to 2024. For live valuation and market cap data, see 166480 company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩48.59 Billion ≈ $32.93 Million |
+147.92% |
| 2023-12-31 | ₩19.60 Billion ≈ $13.28 Million |
-52.73% |
| 2022-12-31 | ₩41.46 Billion ≈ $28.10 Million |
+11.48% |
| 2021-12-31 | ₩37.19 Billion ≈ $25.20 Million |
-9.92% |
| 2020-12-31 | ₩41.29 Billion ≈ $27.98 Million |
-28.44% |
| 2019-12-31 | ₩57.70 Billion ≈ $39.10 Million |
-7.30% |
| 2018-12-31 | ₩62.24 Billion ≈ $42.18 Million |
-5.13% |
| 2017-12-31 | ₩65.60 Billion ≈ $44.46 Million |
-1.69% |
| 2016-12-31 | ₩66.73 Billion ≈ $45.22 Million |
+5.85% |
| 2015-12-31 | ₩63.04 Billion ≈ $42.72 Million |
+232.32% |
| 2014-12-31 | ₩18.97 Billion ≈ $12.86 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to CORESTEM Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8101644225000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩16.44 Billion | 33.82% |
| Other Components | ₩125.60 Billion | 258.47% |
| Total Equity | ₩48.59 Billion | 100.00% |
CORESTEM Inc Competitors by Market Cap
The table below lists competitors of CORESTEM Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Harboes Bryggeri A/S
CO:HARB-B
|
$63.23 Million |
|
Franklin Street Properties Corp
NYSE MKT:FSP
|
$63.25 Million |
|
Bubs Australia Ltd
AU:BUB
|
$63.27 Million |
|
Emkay Global Financial Services Limited
NSE:EMKAY
|
$63.27 Million |
|
LEFORM
KLSE:0266
|
$63.21 Million |
|
Thai Wacoal Public Company Limited
BK:WACOAL
|
$63.21 Million |
|
Histeel
KO:071090
|
$63.19 Million |
|
Ittifak Holding A.S.
IS:LRSHO
|
$63.16 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CORESTEM Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 19,600,629,790 to 48,593,356,060, a change of 28,992,726,270 (147.9%).
- Net loss of 26,252,412,530 reduced equity.
- Share repurchases of 14,006,500,000 reduced equity.
- New share issuances of 14,006,500,000 increased equity.
- Other factors increased equity by 55,245,138,800.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-26.25 Billion | -54.02% |
| Share Repurchases | ₩14.01 Billion | -28.82% |
| Share Issuances | ₩14.01 Billion | +28.82% |
| Other Changes | ₩55.25 Billion | +113.69% |
| Total Change | ₩- | 147.92% |
Book Value vs Market Value Analysis
This analysis compares CORESTEM Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.73x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.78x to 1.73x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩4245.39 | ₩3320.00 | x |
| 2017-12-31 | ₩4173.76 | ₩3320.00 | x |
| 2018-12-31 | ₩3959.83 | ₩3320.00 | x |
| 2019-12-31 | ₩3670.86 | ₩3320.00 | x |
| 2020-12-31 | ₩2626.78 | ₩3320.00 | x |
| 2021-12-31 | ₩2343.62 | ₩3320.00 | x |
| 2022-12-31 | ₩1936.53 | ₩3320.00 | x |
| 2023-12-31 | ₩915.49 | ₩3320.00 | x |
| 2024-12-31 | ₩1921.04 | ₩3320.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CORESTEM Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -54.02%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -91.27%
- • Asset Turnover: 0.24x
- • Equity Multiplier: 2.42x
- Recent ROE (-54.02%) is below the historical average (-28.03%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -58.98% | -52.37% | 0.36x | 3.12x | ₩-7.95 Billion |
| 2015 | -0.81% | -2.76% | 0.25x | 1.19x | ₩-6.82 Billion |
| 2016 | -2.49% | -9.27% | 0.21x | 1.28x | ₩-8.34 Billion |
| 2017 | -6.11% | -22.14% | 0.20x | 1.38x | ₩-10.57 Billion |
| 2018 | -5.46% | -15.22% | 0.25x | 1.43x | ₩-9.62 Billion |
| 2019 | -8.96% | -21.28% | 0.28x | 1.48x | ₩-10.94 Billion |
| 2020 | -56.16% | -87.97% | 0.18x | 3.46x | ₩-27.32 Billion |
| 2021 | -18.82% | -23.14% | 0.22x | 3.67x | ₩-10.72 Billion |
| 2022 | -6.41% | -5.74% | 0.59x | 1.90x | ₩-6.80 Billion |
| 2023 | -90.16% | -52.50% | 0.43x | 4.01x | ₩-19.63 Billion |
| 2024 | -54.02% | -91.27% | 0.24x | 2.42x | ₩-31.11 Billion |
Industry Comparison
This section compares CORESTEM Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $368,573,438,392
- Average return on equity (ROE) among peers: 0.96%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CORESTEM Inc (166480) | ₩40.62 Billion | -58.98% | 1.79x | $63.21 Million |
| ORIENTBIO Inc. (002630) | $57.60 Billion | 0.00% | 0.70x | $43.15 Million |
| Green Cross (005250) | $1.51 Trillion | 0.20% | 0.84x | $425.10 Million |
| Green Cross Holdings Preference Shares (005257) | $1.85 Trillion | 1.30% | 0.98x | $3.74 Million |
| Pharmicell (005690) | $51.52 Billion | 8.44% | 0.23x | $736.42 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $49.94 Million |
| HLB Co. Ltd (028300) | $19.44 Billion | 0.00% | 0.66x | $5.41 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $37.00 Billion | 2.34% | 0.69x | $19.29 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $37.92 Million |
| Hyundai Bioscience Co. Ltd (048410) | $58.24 Billion | 3.27% | 0.77x | $872.13 Million |
| iNtRON Biotechnology Inc (048530) | $11.93 Billion | -9.93% | 0.65x | $77.34 Million |
About CORESTEM Inc
CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatm… Read more